Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows (in millions, except percentages):

	Three Months Ended September 30,						Nine Months Ended September 30,
Net sales	2019			2018			2019			2018
MedSurg	$	845		$	746		$	2,429		$	2,207
Rhythm and Neuro	780			740			2,323			2,252
Cardiovascular	1,011			908			3,009			2,806
Reportable segment net sales	2,636			2,393			7,760			7,262
BTG Acquisition(1)	71			n/a			71			n/a
Net sales	$	2,707		$	2,393		$	7,831		$	7,262
	Three Months Ended September 30,						Nine Months Ended September 30,
Income (loss) before income taxes	2019			2018			2019			2018
MedSurg	$	319		$	274		$	870		$	807
Rhythm and Neuro	166			168			488			481
Cardiovascular	281			268			857			858
Operating income of reportable segments	766			710			2,216			2,146
BTG Acquisition(1)	16			n/a			16			n/a
Corporate expenses, including hedging activities	(75		)	(97		)	(215		)	(297		)
Intangible asset impairment charges, acquisition/divestiture-related, restructuring- and restructuring-related, litigation-related net (charges) credits and medical device regulation charges	(146		)	(77		)	(210		)	(225		)
Amortization expense	(178		)	(148		)	(498		)	(437		)
Operating income (loss)	383			388			1,308			1,187
Other expense, net	(292		)	68			(615		)	(61		)
Income (loss) before income taxes	$	91		$	456		$	693		$	1,126
Reportable segment operating income as a percentage of reportable segment net sales	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
MedSurg	37.8		%	36.8		%	35.8		%	36.6		%
Rhythm and Neuro	21.3		%	22.7		%	21.0		%	21.4		%
Cardiovascular	27.8		%	29.5		%	28.5		%	30.6		%